Cytogenetic Evolution in Patients with IPSS Low and Intermediate-1 Risk. Study from the Spanish Group of Myelodysplastic Syndrome

被引：0
|
作者：
Marcel Merchan, Brayan [1 ]
Ortega, Margarita [1 ]
Jose Llamas-Poyato, Mara [2 ]
Cortes, Montserrat [3 ]
Arnan, Montserrat [4 ]
Cervero, Carlos [5 ]
Montoro, Julia [1 ]
Gimenez, Teresa [6 ]
Lopez, Mara [7 ]
Arenillas, Leonor [8 ]
Valcarcel, David [1 ]
机构：
[1] Univ Hosp Vall dHebron, Barcelona, Spain
[2] Hosp Reina Sofia, Cordoba, Spain
[3] Fundacio Hosp Asil, Dept Hematol, Granollers, Spain
[4] Inst Catala Oncol Duran & Reynals, Barcelona, Spain
[5] Hosp Virgen La Luz, Dept Hematol, Cuenca, Spain
[6] Hosp Joan 23, Tarragona, Spain
[7] Hosp Univ La Fe, Valencia, Spain
[8] Hosp del Mar, GRENTHE, IMIM Hosp del Mar Res Inst, Barcelona, Spain
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] ACQUISITION OF CYTOGENETIC ABNORMALITIES IN PATIENTS WITH IPSS LOW AND INTERMEDIATE-1 RISK. STUDY FROM THE SPANISH GROUP OF MYELODYSPLASTIC SYNDROME
    Merchan, B.
    Ortega, M.
    Llamas-Poyato, M. J.
    Cortes, M.
    Arnan, M.
    Cervero, C.
    Montoro, J.
    Gimenez, T.
    Lopez, M.
    Arenillas, L.
    Valcarcel, D.
    [J]. LEUKEMIA RESEARCH, 2015, 39 : S136 - S136
  • [2] OUTCOMES OF CONTINUED AZACITIDINE TREATMENT FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME IN IPSS LOW AND INTERMEDIATE-1
    Moon, J. H.
    Sohn, S. K.
    Cho, Y. Y.
    Kim, Y. K.
    Kim, H. J.
    Kim, M. K.
    Do, Y. R.
    Song, M. K.
    Lee, W. K.
    Lee, S. M.
    Kim, H.
    Won, J. H.
    Yeon, J. Deok
    [J]. HAEMATOLOGICA, 2012, 97 : 141 - 141
  • [3] The in vitro effect of SB-497115 (Eltrombopag) on megakaryopoiesis of patients with low/intermediate-1 IPSS myelodysplastic syndrome
    Papadaki, H.
    Mavroudi, I.
    Psyllaki, M.
    Pyrovolaki, K.
    Papadaki, V.
    Kalpadakis, C.
    Mastrodimou, S.
    Kaparou, M.
    Kanellou, P.
    Gvazava, G.
    [J]. LEUKEMIA RESEARCH, 2009, 33 : S47 - S48
  • [4] Improved survival rates with continued treatment with hypomethylating agents in patients with myelodysplastic syndrome in IPSS low and intermediate-1
    Moon, J.
    Sohn, S. K.
    Kim, Y. K.
    Kim, H. J.
    Lim, S. N.
    Kim, M. K.
    Do, Y. R.
    Song, M. K.
    Lee, W. S.
    Lee, S. M.
    Kim, H.
    Won, J. H.
    Jo, D. Y.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S165 - S166
  • [5] PHASE 1 SAFETY OUTCOMES OF MESENCHYMAL STROMAL STEM CELL THERAPY IN PATEINTS WITH LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROME
    Cirillo, M.
    Carnley, B.
    Tan, P.
    Tan, D.
    Sturm, M.
    [J]. CYTOTHERAPY, 2018, 20 (05) : S31 - S31
  • [6] Clinical and Biological Characterization of Patients with Low/Intermediate-1 Risk Myelodysplastic Syndrome and Iron Overload
    Ivars, David
    Collado, Rosa
    Alguero, Carmen
    Carmen Tormos, M.
    Diaz, Laura
    Luis Garcia-Ghnenez, Jose
    Arrizabalaga, Beatriz
    Orero, Mayte
    Perez, Pedro
    Sanchez, Magdalena
    Angeles Ruiz, M.
    Yaguee, Nuria
    Sancho-Tello, Reyes
    Regadera, Ana
    Tormo, Mar
    Egea, Mercedes
    Vidal, Elena
    Enrique O'Connor, J.
    Saez, Guillermo T.
    Carbonell, Felix
    [J]. BLOOD, 2012, 120 (21)
  • [7] LONG TERM FOLLOW UP OF 5 PATIENTS TREATED WITH MESENCHYMAL STROMAL CELL IMMUNOMODULATORY THERAPY FOR LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROME
    Tan, D.
    Carnley, B.
    Sturm, M.
    Cirillo, M.
    [J]. CYTOTHERAPY, 2024, 26 (06) : S40 - S40
  • [8] ELTROMBOPAG FOR THE TREATMENT OF THROMBOCYTOPENIA OF LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS OF A PROSPECTIVE, RANDOMIZED, TRIAL
    Oliva, E.
    Santini, V.
    Zini, G.
    Palumbo, G.
    Poloni, A.
    Cortelezzi, A.
    Rodeghiero, F.
    Voso, M.
    Molteni, A.
    Sanpaolo, G.
    Liberati, A.
    Morabito, F.
    Balleari, E.
    Impera, S.
    Salvi, F.
    Spiriti, M.
    Marino, A.
    Roda, F.
    Alati, C.
    Ronco, F.
    Raimondo, F.
    Leoni, P.
    Alimena, G.
    Fioritoni, G.
    Latagliata, R.
    Nobile, F.
    [J]. HAEMATOLOGICA, 2013, 98 : 456 - 456
  • [9] Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: Results of a prospective, randomized trial
    Oliva, E. N.
    Santini, V.
    Zini, G.
    Palumbo, G. A.
    Poloni, A.
    Cortelezzi, A.
    Rodeghiero, F.
    Voso, M. T.
    Molteni, A.
    Sanpaolo, G.
    Liberati, M.
    Morabito, F.
    Balleari, E.
    Impera, S.
    Salvi, F.
    Spiriti, M. A. Aloe
    Marino, A.
    Roda, F.
    Alati, C.
    Ronco, F.
    Di Raimondo, F.
    Leoni, P.
    Alimena, G.
    Latagliata, R.
    Nobile, F.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S162 - S162
  • [10] Diagnostic procedures and treatment of patients with Myelodysplastic Syndromes (MDS) of low and intermediate-1 risk. Results of the outpatient MDS registry
    Schmitz, S.
    Boettger, I
    Schnell, R.
    Lerchenmueller, C.
    Sauer, A.
    Severin, K.
    Germing, U.
    Steinmetz, H. T.
    [J]. ONKOLOGIE, 2012, 35 : 148 - 148
12345